Tuesday, May 21, 2013 Last update: 6:35 PM
Company Tech News as it Breaks
Trade Events
Derma Sciences, Inc.
News articles for Derma Sciences, Inc.:
Thursday, May 16, 2013
- Derma Sciences Reports First Quarter 2013 Financial ResultsDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three months ended March ... read more
Tuesday, May 14, 2013
- Derma Sciences Engages Plexus Ventures to Explore Strategic Options for DSC127 Outside the U.S.Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that it has engaged Plexus Ventures, a leading strategic advisor to ... read more
Thursday, April 25, 2013
- Derma Sciences Begins Screening Patients in Second Phase 3 Trial with DSC127 for Healing Diabetic Foot UlcersDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase ... read more
Monday, April 1, 2013
- Derma Sciences Expands TCC-EZ® Market Reach with Long-Term Exclusive Global Rights AgreementDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that it has signed a long-term exclusive global rights agreement ... read moreDerma Sciences Reports 2012 Fourth Quarter and Full Year Financial ResultsDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the fourth quarter and year ... read more
Friday, March 15, 2013
- Derma Sciences Announces Timing for Fourth Quarter Conference Call and 2012 Form 10-K FilingDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will file its Form 10-K for 2012 ... read more
Wednesday, February 6, 2013
- Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot UlcersDerma Sciences, Inc. (the “Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that enrollment of patients has commenced in the first ... read more
Friday, November 30, 2012
- Derma Sciences to Present at Two Upcoming ConferencesDerma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J. Quilty, the Company’s chief executive officer, will ... read more